Literature DB >> 8643600

Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix.

M Roth1, O Eickelberg, E Kohler, P Erne, L H Block.   

Abstract

The extracellular matrix (ECM) is an intricate network composed of an array of macromolecules capable of regulating the functional responsiveness of cells. Its composition greatly varies among different types of tissue, and dysregulation of its metabolism may contribute to vascular remodeling during the pathogenesis of various diseases, including atherosclerosis. In view of their antiatherosclerotic effects, the role of Ca2+ channel blockers in the metabolism of ECM was examined. Nanomolar concentrations of the five Ca2+ channel blockers amlodipine, felodipine, manidipine, verapamil, or diltiazem significantly decreased both the constitutive and platelet-derived growth factor BB-dependent collagen deposition in the ECM formed by human vascular smooth muscle cells and fibroblasts. The drugs inhibited the expression of fibrillar collagens type I and III and of basement membrane type IV collagen. Furthermore, Ca2+ channel blockers specifically increased the proteolytic activity of the 72-kDa type IV collagenase as shown by gelatin zymography and inhibited the transcription of tissue inhibitor of metalloproteinases-2.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8643600      PMCID: PMC39271          DOI: 10.1073/pnas.93.11.5478

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  Inhibition of interleukin 1-induced biosynthesis of stromelysin by the calcium antagonist TMB-8 (8-(N, N-diethylamino)octyl-3,4,5-trimethoxybenzoate HCl).

Authors:  V M Baragi; A M Sweet; M A Thompson; K L Hawkins; K A Toy; W S Rosebury
Journal:  Connect Tissue Res       Date:  1995       Impact factor: 3.417

Review 2.  Matrix metalloproteinases and their inhibitors in connective tissue remodeling.

Authors:  J F Woessner
Journal:  FASEB J       Date:  1991-05       Impact factor: 5.191

Review 3.  Collagen family of proteins.

Authors:  M van der Rest; R Garrone
Journal:  FASEB J       Date:  1991-10       Impact factor: 5.191

4.  Manidipine regulates the transcription of cytokine genes.

Authors:  M Roth; R Keul; L R Emmons; W H Hörl; L H Block
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

5.  Effects of collagen matrix on proliferation and differentiation of vascular smooth muscle cells in vitro.

Authors:  N Sakata; K Kawamura; S Takebayashi
Journal:  Exp Mol Pathol       Date:  1990-04       Impact factor: 3.362

Review 6.  Dynamic state of collagen: pathways of collagen degradation in vivo and their possible role in regulation of collagen mass.

Authors:  G J Laurent
Journal:  Am J Physiol       Date:  1987-01

7.  The sequence of cell and matrix changes in atherosclerotic lesions of coronary arteries in the first forty years of life.

Authors:  H C Stary
Journal:  Eur Heart J       Date:  1990-08       Impact factor: 29.983

8.  Localization of PDGF-B protein in macrophages in all phases of atherogenesis.

Authors:  R Ross; J Masuda; E W Raines; A M Gown; S Katsuda; M Sasahara; L T Malden; H Masuko; H Sato
Journal:  Science       Date:  1990-05-25       Impact factor: 47.728

9.  Collagens in human atherosclerosis. Immunohistochemical analysis using collagen type-specific antibodies.

Authors:  S Katsuda; Y Okada; T Minamoto; Y Oda; Y Matsui; I Nakanishi
Journal:  Arterioscler Thromb       Date:  1992-04

10.  Ca(2+)-channel blockers modulate expression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and low density lipoprotein receptor genes stimulated by platelet-derived growth factor.

Authors:  L H Block; H Matthys; L R Emmons; A Perruchoud; P Erne; M Roth
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

View more
  28 in total

1.  Effects of amlodipine and lacidipine on cardiac remodelling and renin production in salt-loaded stroke-prone hypertensive rats.

Authors:  J Kyselovic; P Krenek; M Wibo; T Godfraind
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

Review 2.  Treatment of Peyronie's disease: 2012 update.

Authors:  Ege Can Serefoglu; Wayne J G Hellstrom
Journal:  Curr Urol Rep       Date:  2011-12       Impact factor: 3.092

Review 3.  Extracellular matrix molecules: potential targets in pharmacotherapy.

Authors:  Hannu Järveläinen; Annele Sainio; Markku Koulu; Thomas N Wight; Risto Penttinen
Journal:  Pharmacol Rev       Date:  2009-06       Impact factor: 25.468

Review 4.  Nonsurgical treatment options in Peyronie's Disease: 2016 update.

Authors:  Raidh A Talib; Mohammed Abdulkareem Ibrahim; Önder Cangüven
Journal:  Turk J Urol       Date:  2016-12

Review 5.  2013-2014 updates in Peyronie's disease management.

Authors:  Benjamin A Sherer; Krishnan Warrior; Laurence A Levine
Journal:  Curr Urol Rep       Date:  2014-12       Impact factor: 3.092

6.  Peyronie's Disease: A Review.

Authors:  Mark Jalkut; Nestor Gonzalez-Cadavid; Jacob Rajfer
Journal:  Rev Urol       Date:  2003

7.  Distinct effects of Broncho-Vaxom (OM-85 BV) on gp130 binding cytokines.

Authors:  M Roth; L H Block
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

8.  Influence of serum cholesterol on atherogenesis and intimal hyperplasia after angioplasty: inhibition by amlodipine.

Authors:  Mark B Kahn; Kathleen Boesze-Battaglia; David W Stepp; Artium Petrov; Yong Huang; R Preston Mason; Thomas N Tulenko
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-09-23       Impact factor: 4.733

9.  New Generation Calcium Channel Blockers in Hypertensive Treatment.

Authors:  Yuri Ozawa; Koichi Hayashi; Hiroyuki Kobori
Journal:  Curr Hypertens Rev       Date:  2006-05-01

10.  Inhibition of collagen synthesis by select calcium and sodium channel blockers can be mitigated by ascorbic acid and ascorbyl palmitate.

Authors:  Vadim Ivanov; Svetlana Ivanova; Tatiana Kalinovsky; Aleksandra Niedzwiecki; Matthias Rath
Journal:  Am J Cardiovasc Dis       Date:  2016-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.